



IOL Chemicals and Pharmaceuticals Limited


**Investor Presentation** 

August 2021



This information may contain certain forward-looking statements/details in the current scenario, which is extremely dynamic and increasingly fraught with risks and uncertainties. Actual results, performances, achievements or sequence of events may be materially different from the views expressed herein. Investors/shareholders/public are hence cautioned not to place undue reliance on these statements/details, and are advised to conduct their own investigation and analysis of the information contained or referred to in this section be before taking any action with regard to their own specific objectives. Further, the discussion following here in reflects the perceptions on major issues as on date and the opinions expressed here are subject to change without notice. The Company under takes no obligation to publicly update or revise any of the opinions or forwardlooking statements expressed in this section, consequent to new information, future events or otherwise.







#### Values

We, at IOLCP, believe values bring character to any organization that help leaders to guide teams for a culture of excellence through continuous improvements.



Catering to the top-tier players across diverse important industries like pharmaceuticals, ink industry, flexible packaging, adhesives, surface coatings, flavours, paints & lamination and essences etc.



Captive co-generation unit with capacity of 17 MW to meet power and steam requirements



To be amongst the most admired companies in APIs, Intermediates and Specialty Chemicals globally.

### 🕑 Mission

To provide top quality products in APIs, Intermediates and Specialty Chemicals through continuous innovation and cutting-edge technology with due regards to safety and environment.

#### Key Highlights





employees



Debt free company, No debt raised since 2017



Largest producer of Ibuprofen and the only company worldwide being backward integrated with ~35% Global share



Spread over a sprawling campus of over 100 acres



Largest producer of Ethyl Acetate at Single Location in India



Zero Discharge Effluent Treatment Plant 2nd Largest producer of Iso Butyl Benzene (IBB) with ~30% Global share



Customer base across 80 countries



Over 20 products are commercialised with 8 products in pipeline



Credit Rating: A+, outlook; stable (Care Ratings Limited)





Mr. Varinder is an industrialist and has wide and rich experience of more than 35 years in the chemical & fertilizer industry and along with a comprehensive approach and strong Pharma API industry oversight has paved a way for innovation and excellence.

Varinder Gupta (Managing Director)



Vikas Gupta (Executive Director)

Mr. Vikas is academically equipped with the knowledge and possesses organizational capacity. He has worked in strategic department of the company and played a main role in guiding the Chemical and Pharmaceutical business of the company. He has been vital to the functioning of the company over the last 7 years.



Dr. Sanjay Chaturvedi (Chief Executive Officer) Dr. Sanjay is a seasoned global business executive having worked in the specialty chemicals and pharmaceutical industry for over 25 years in companies like Praj Industries, Dr. Reddy's, among few others. Aurobindo He brings a demonstrated track record along with functional expertise in Sales, Marketing, Strategy, Manufacturing and R&D in USA and in India.



Kushal Kumar Rana (Director - Works)

Mr. Kushal comes from a strong technical background having done his Bachelor's in Chemistry, Physics, Math and Master's degree in Chemistry. He has a rich experience of over 30 years in the pharmaceutical industry in companies like Morepen Laboratories, Chemiplast Industries His expertise lies in looking after quality assurance, quality control & corporate regulatory affairs.





Rajender Mohan Malla (Chairman and Independent Director)

- Mr. Rajender has very distinguished career of four decades.
- He had held top and significant decisionmaking positions in Banks, Financial Institutions & NBFCs.
- In his most recent executive roles, he was MD & CEO of PTC India Financial Services Limited (PFS), and prior to that CMD of IDBI.



Dr. Sandhya Mehta (Independent Director)

- Dr. Sandhya is working as the principal of Guru Nanak Institute of Management & technology, Ludhiana and has vast 22 year experience to her credit.
- She has published seven books in addition to numerous papers published in reputed National & international Journals.




Harpal Singh (Independent Director)

- Mr. Harpal has had over 35 year's experience of banking and financial services.
- Most recently he was General Manager of Punjab National Bank and headed entire operations of bank in State of Punjab from 2010 to 2015.

Our Journey





#### **Certifications and Accreditations**






## Product Segmentation





IOLCP is the largest producer of Ibuprofen with ~35% Global share and the only company worldwide being backward integrated for all Intermediates and Key Starting Material of Ibuprofen





Among the largest producer of Metformin in world



Added more than 7 new products in its API portfolio basket in last two years



Product portfolio that caters to over 7 therapeutic category

#### Product application across various therapeutic areas





Anti -

Pain Diabetic Management

Anti -

Platelet







Anti -

Anti -Convulsant Cholelithic

Proton **Pump Inhibitor** 



API - Commercialized	API - Pipeline	
Ibuprofen	Fexofenadine	
Ibuprofen Lysinate		
Ibuprofen Sodium	Quetiapine Fumarate	
Dex-Ibuprofen		
Metformin HCL	Dextromethorphan	
Clopidogrel Bisulphate (Form II)	Apixaban	
Pantoprazole Sodium		
Fenofibrate (Micronised)	Mesalazine	
Gabapentin	Nebivolol	
Lamotrigine		
Ursodeoxycholic Acid	Lisinopril	
Losartan Potassium		
Levetiracetam	Valsartan	





IOLCP first commenced manufacturing Ethyl Acetate in 1996, with a starting capacity of 3000 tonnes per annum. Today, the Company has grown this business to become the largest single location plant in India, with a production capacity of 100,000 tonnes per annum.





India's second largest manufacturer for Iso Butyl Benzene (IBB) with ~30% global share



IBB, MCA and Acetyl Chloride are key starting materials for Ibuprofen



Captive consumption of Mono Chloro Acetic Acid with 7,200 TPA capacity



Asia's first continuous dual technology (green chemistry) plant for MCA and Acetyl Chloride

#### Product application across diversified industries



Food Processing Packaging

Flexible



Pharma

Chemical Intermediate






Ink



**Paints** Pesticides

















API manufactured in batch manner and intermediates & Specialty chemicals in continuous product delivery manner based on DCS technology



Dedicated blocks involved in manufacturing of APIs



Facility is coupled with ISO class-8 HVAC system, PSA Nitrogen & Purified water along with 127 MTPH steam generation capacity with multiple boilers



Manufacturing facilities involves - Reactions, Filteration, Centrifugation, Drying, Blending & Sieving, Micronization operation



Four stage treatment zero discharge ETP, solvent recovery plants & EHS cell as a part of the facility



Dedicated decentralized utilities from -20 to 275 deg.C temp and dedicated cogeneration plant of 17MW

#### Research & Development



R&D facility is in action 24\*7



Working on generic molecules with latest equipment & techniques for process development



DSIR approved facility for research & development



In-house development of multi step products

#### Our Core Sustainability Pillars





- minimize the adverse impact on Strive to environment, health and Safety by upgrading technology, optimum utilization of resources and minimizing effluent / waste generation.
- Complying with the applicable statutory and legal requirements providing safe working and environment / work place by imparting training to all employees.
- Spread awareness about the EMS and Process Safety and necessary PPE.

#### Environment



- Construction and renovation of school locations, provided technical equipment for smart education
- Primary healthcare including sanitation
- Disaster relief by eradicating hunger, poverty and malnutrition
- Community development by setting up old age
- homes and community mentally retarded home
- Protection of art and culture
- Plantation in villages for restoration to environment
- Trust/Contribution

#### Corporate Social Responsibility

#### Solar Lights donated by IOLCP

जिम्मेदार भाते हुए महानगर व



याना में 35 सोलर स्ट्रीट लाइटें वताया कि मैनेजिंग डायरैक्टर वरिन्द्र गप्ता की देखरेख में पहले भी महानगर के कई सरकारी स्कलों को अपग्रेड किया जा

चका है। इसके अलावा कोविड महामारी थे। इस मौके जैन व नवीन कमार भी उपस्थित

#### Plantation activity conducted by IOLCP in Barnala



# Financial Overview






Financial			
Summary (INR Cr)	Q1FY22	Q4FY21	Q1FY21
Total Income	524	467	466
Gross Profit	189	189	218
EBITDA	116	117	158
PAT	67	75	128


#### 5 years Financial Performance - Annually




Revenues & Margins\* - Annual




Margin\* Expansion - Over the Years



Segmental EBIT %



Debt/Equity




\*All Profits and Total Income include Other Income


#### **Quarterly Financial Performance**



Revenues & Margins\*




Segmental EBIT %



\*All Profits and Total Income include Other Income; PAT for Q1FY22 includes Exceptional Items





Domestic Export



Balance Sheet (INR Crs)	FY17	FY18	FY19	FY20	FY21
Shareholder's Funds	188.7	215.7	474.3	813.5	1260.4
Debt	446.5	421.9	284.0	56.0	0.0
Other Long Term Liabilities	17.2	33.6	20.8	79.7	59.1
Other Current Liabilities	165.1	180.9	162.8	220.6	290.6
Equity & Liabilities	817.5	852.1	941.9	1169.8	1610.1
Fixed Assets	395.1	412.6	438.7	488.2	560.6
Other Non Current Assets	8.8	14.8	15.1	10.7	27.2
Non Current Assets	403.9	427.4	453.8	498.9	587.8
Investments	0.1	0.1	0.1	0.1	1.2
Cash & Bank Balances	16.8	17.3	29.6	154.7	364.7
Other Current Assets	396.7	407.3	458.4	516.1	656.4
Current Assets	413.6	424.7	488.1	670.9	1022.3
Assets	817.5	852.1	941.9	1169.8	1610.1




P&L (INR Crs)	FY17	FY18	FY19	FY20	FY21	Q1FY22	Q4FY21	Q1FY21
Revenues	710.6	983.3	1,685.3	1,894.5	1,967.0	518.5	460.4	460.1
Other Income	1.3	6.3	10.4	16.0	24.3	5.7	6.2	5.8
Total Income	711.9	989.6	1,695.7	1,910.5	1,991.3	524.2	466.6	465.9
Gross Profits	234.5	294.4	648.5	845.5	888.4	189.2	188.9	217.7
Gross Profits %*	32.9%	<b>29.7</b> %	38.2%	44.3%	44.6%	36.1%	40.5%	46.7%
EBITDA	103.4	125.9	420.0	589.9	616.1	115.9	117.4	157.9
EBITDA %*	14.5%	12.7%	24.8%	<b>30.9</b> %	30.9%	22.1%	25.2%	33.9%
Depreciation	29.8	30.2	32.5	35.7	38.9	10.3	10.0	9.4
EBIT	73.6	95.7	387.6	554.2	577.2	105.6	107.4	148.5
EBIT %*	10.3%	<b>9.7</b> %	22.9%	29.0%	29.0%	20.1%	23.0%	31.9%
Interest	67.7	64.4	51.4	20.9	5.8	1.8	1.4	1.8
Earnings before exceptional items and taxes	5.9	31.3	336.2	533.3	571.4	103.8	106.0	146.7
Exceptional Items	-	-	-	-	-	13.9	-	-
Taxes	1.2	3.6	99.5	172.0	126.8	22.9	30.7	19.2
РАТ	4.7	27.7	236.7	361.3	444.6	67.0	75.3	127.5
PAT %*	0.7%	2.8%	14.0%	<b>18.9</b> %	22.3%	12.8%	16.1%	27.4%


#### Shareholder Information

P

Stock Data (As on 30 <sup>th</sup> June, 2021)				
\$	Market Capitalization (₹)	3,569Crs		
$\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{\mathbf{$	Face Value(₹)	10		
~	Share Price (₹)	608.1		
3	EPS (₹)	11.4		
$\uparrow$	52-Week High (₹)	898.4		
$\downarrow$	52-Week Low (₹)	516.3		
Q	Symbol(NSE/BSE)	IOLCP   524164		



#### IOLCP 5 Years Stock Price vs Sensex







### Thank You

For further details: Mr. Pardeep Kumar Khanna , CFO Email: <u>pardeepkhanna@iolcp.com</u> Phone: +91-161-2225531-35